Latest News and Press Releases

  AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103 DUBLIN, Ireland, and Boston MA, September 15 2020,  Amryt (Nasdaq: AMYT,...

AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020 New revenue guidance of $170M - $175M in 2020 Conference call and webcast today 0830 ET / 1330 BST DUBLIN,...

  AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE Monday, August 3, 2020 at 1000 ET / 1500 BST DUBLIN, Ireland, and...

June 3, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE...

May 11, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) FY 2019 RESULTS Transformational year of performance and growth for AmrytAegerion integration...

May 11, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) Q1 2020 RESULTS $44.6M unaudited Q1 revenues representing a 30% increase on unaudited combined revenues of...

17 October 2018AIM: AMYTESM: AYP Amryt Pharma plc(“Amryt” or the “Company”) Lojuxta to be reimbursed in France Amryt’s lead commercial product now available in all five of the EU’s largest markets ...

10 September 2018AIM: AMYT ESM: AYP Amryt Pharma plc(“Amryt” or the “Company”) Amryt receives IND approval from FDA for AP101 enabling the opening of US clinical trial sites             Amryt, a...

9 July 2018AIM: AMYT Amryt Pharma plc(“Amryt” or the “Company”) NHS England approves funding for Lojuxta Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to...